ZyVersa Therapeutics, Inc.

Corporate News Releases

Nov 13, 2019 • 7:08 AM EST ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Stifel 2019 Healthcare Conference

Oct 28, 2019 • 7:08 AM EDT ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Inaugural Inflammasome Therapeutics Summit on October 30th, 2019

Oct 14, 2019 • 7:08 AM EDT ZyVersa Therapeutics' Viewpoint on "Why Kidney Indications Are Coming into Sharp Focus" Reported in BIOCENTURY Innovations' Article

Sep 25, 2019 • 6:55 AM EDT Interview with ZyVersa Therapeutics' CEO, Stephen C. Glover, Published in CEOCFO Magazine

Sep 19, 2019 • 7:03 AM EDT ZyVersa Therapeutics Unveils a White Paper Fostering Education About Inflammasomes and Their Potential as a Promising Therapeutic and Diagnostic Target for Inflammatory Diseases

Sep 12, 2019 • 7:08 AM EDT ZyVersa Therapeutics' Perspectives on Inflammasomes Reported in BIOCENTURY Innovations Article

Sep 5, 2019 • 7:00 AM EDT ZyVersa Therapeutics Advances Development of Lead Inflammasome Inhibitor Candidate, IC 100

May 28, 2019 • 7:08 AM EDT ZyVersa Therapeutics to Attend the World's Largest Biotechnology Partnering Event, BIO International (Philadelphia, June 3 - 6, 2019)

May 23, 2019 • 7:08 AM EDT ZyVersa Therapeutics Announces Appointment of International Investor, Andrew (DW) Kim, to its Board of Directors

May 21, 2019 • 7:08 AM EDT Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board